Tag Directory / WEIGHTLOSS     showing 1–1 of 1   RSS

for: Tuesday, June 09, 2026



Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

Richard E. Pratley / nature - Nature Medicine, Published online: 08 June 2026; doi:10.1038/s41591-026-04440-4In the phase 2 EMBRAZE study, participants receiving tirzepatide and apitegromab lost less lean mass compared to participants receiving tirzepatide and placebo.

AI Summary: A randomized, double‑blind phase 2 trial found apitegromab helped preserve lean mass in people losing weight on tirzepatide (a GLP‑1–class obesity medication). The drug reduced treatment‑associated muscle wasting without undermining weight loss, positioning apitegromab as a potential adjunct for patients worried about strength and frailty during aggressive metabolic therapy.

8 GLP-1 findings to know

23 days / beckershospitalreview / Ella Jeffries

Can use of popular weight loss medications reduce behaviors linked to violent crime?

24 days / medicalxpress

Tirzepatide outperformed semaglutide weight-loss drug results in real world patients, study shows

24 days / medicalxpress

Study finds exercise decreases among people taking GLP-1 medication

27 days / medicalxpress

Drug apitegromab may stop muscle loss when taking weight loss drugs

4 wks / medicalxpress

Ozempic butt: Drug to stop muscle loss side effect of obesity jabs

4 wks / bbc

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

4 wks / nature / Richard E. Pratley



Back to Top


WEIGHTLOSS Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pfizer, Cancer Research, Long COVID, Mergers and Acquisitions and look for the RSS link.

Back to Top
↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.